Sparks flew both ways Sept. 4 as Democratic senators pushed for Robert Kennedy to resign as secretary of the U.S. Department of Health and Human Services (HHS) during a Senate Finance Committee hearing ostensibly held to discuss the Trump administration’s 2026 health care agenda. But with Kennedy the only witness, the hearing focused on Kennedy’s perceived failings as HHS secretary. “The United States is in the midst of a health care calamity,” Ranking Member Ron Wyden, D-Ore., said in his opening comments, which were laden with personal attacks. Read More
About two years since its founding, new company Radiance Biopharma Inc. signed a deal in which it could pay up to $1.165 billion to Novatim Immune Therapeutics Co. Ltd. for global rights outside of certain Asian countries to a bispecific nanobody antibody-drug conjugate that targets c-MET and EGFR to treat solid tumors. Read More
Roivant Sciences Ltd.’s Immunovant Inc. unit unveiled phase II data in Graves’ disease with batoclimab, whetting appetites on Wall Street for the results with next-generation prospect IMVT-1402 from two potentially registrational trials that are enrolling now. Read More
Phase III results from Sanofi SA’s study of amlitelimab in treating atopic dermatitis met the primary and key secondary endpoints, but investors took a step back. Read More
The funding is in place for a phase IIb trial of its lead gut microbiome live biotherapeutic, after MRM Health NV closed a €55 million (US$64 million) series B round. Read More
“New explosions in biotechnology are allowing us to interrogate cancers at a very sophisticated level compared to before,” Dennis Slamon told audience members at the Global Bio Conference in Seoul, South Korea Sept. 3. Read More
Propanc Biopharma, Inc. plans to acquire $100 million of Ethereum cryptocurrency over the next 12 months to accelerate its pipeline. The company is advancing its lead candidate, PRP, to enter a phase Ib trial in 30 to 40 advanced cancer patients with malignant solid tumors. Read More
Researchers from the CUNY Advanced Science Research Center and their collaborators recently published a paper in Science Advances on Aug. 27, 2025, about synthetic carbohydrate receptors (SCRs) and their potential as broad-spectrum antivirals by targeting the viral envelope N-glycans. They described the antiviral activity of a series of tetrapodal SCRs both in vitro and in vivo, showing their potential as broad-spectrum inhibitors of viral infection. Read More
New hires and promotions in the biopharma industry, including: Adagene, Allegro, Alltrna, Cancervax, Cartography, Fractyl, Kymera, Lixte, NMD, Oligomerix, Palvella, Parabilis, Pretzel, Stratus. Read More
Regulatory snapshots, including global drug submissions and approvals, and other regulatory decisions and designations: Achieve Life Sciences, Ascelia, Bioarctic, Eisai, Varmx. Read More
